Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Conduit Pharmaceuticals Inc. (CDTTW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CDTTW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -64.29% | Avg. Invested days 6 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 38318 | Beta 2.27 | 52 Weeks Range 0.01 - 0.10 | Updated Date 04/1/2025 |
52 Weeks Range 0.01 - 0.10 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -168.82% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 6508112 |
Shares Outstanding - | Shares Floating 6508112 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Conduit Pharmaceuticals Inc.
Company Overview
History and Background
Conduit Pharmaceuticals Inc. was incorporated in 2021, resulting from a merger with Murphy Canyon Acquisition Corp, aiming to acquire and develop late-stage drug candidates, particularly in the treatment of autoimmune diseases.
Core Business Areas
- Drug Development: Focuses on acquiring and developing late-stage drug candidates with proven mechanisms of action and clinical data. They aim to accelerate development and commercialization.
Leadership and Structure
Dr. Allan Shaw is the CEO, leading the company's strategic direction and development efforts. The organizational structure is designed to facilitate efficient drug development and partnering.
Top Products and Market Share
Key Offerings
- AZD1656 (ex-AstraZeneca): A Phase III ready compound for chronic hyperglycemia in type 2 diabetes and potentially other endocrine/metabolic disorders. They are currently conducting the Phase III trial. Competitors include companies developing similar treatments, such as Novo Nordisk and Eli Lilly.
- Remibrutinib (ex-Roche): A Phase III ready compound that inhibits Bruton's tyrosine kinase (BTK) that can be used for immune mediated diseases with focus on Rheumatoid Arthritis. They are currently conducting Phase III trials. Key competitors include companies that are developing and selling rheumatoid arthritis therapeutics, like AbbVie (Humira), and Johnson and Johnson (Stelara).
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and research-intensive, with a growing focus on precision medicine and targeted therapies. It is also subject to extensive regulatory oversight.
Positioning
Conduit Pharmaceuticals aims to differentiate itself by focusing on late-stage assets, aiming to reduce development risk and accelerate time to market. This strategy can potentially streamline the drug development process but relies on successful trial outcomes and regulatory approvals.
Total Addressable Market (TAM)
The TAM for treatments for type 2 diabetes, rheumatoid arthritis, and related endocrine and immune-mediated diseases is substantial, estimated at several billion USD annually. Conduit Pharmaceuticals is positioned to capture a portion of this market through successful development and commercialization of its drug candidates.
Upturn SWOT Analysis
Strengths
- Late-stage drug candidates
- Experienced leadership team
- Focus on well-defined therapeutic areas
Weaknesses
- Limited pipeline diversity
- Reliance on successful clinical trials
- Lack of commercialization infrastructure
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Favorable regulatory changes
Threats
- Clinical trial failures
- Competition from established players
- Pricing pressures
Competitors and Market Share
Key Competitors
- Novo Nordisk (NVO)
- Eli Lilly and Company (LLY)
- AbbVie (ABBV)
- Johnson & Johnson (JNJ)
Competitive Landscape
Conduit Pharmaceuticals is a relatively small player compared to the established pharmaceutical giants in the autoimmune and endocrine spaces. Its competitive advantage lies in its focus on late-stage assets, which could potentially accelerate time to market. However, it faces significant competition and requires successful clinical trial outcomes to compete effectively.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily through asset acquisition and clinical development initiation rather than revenue generation.
Future Projections: Future growth will depend on successful clinical trial outcomes and regulatory approvals for AZD1656 and Remibrutinib.
Recent Initiatives: Recent initiatives include advancing AZD1656 and Remibrutinib into late-stage clinical development and exploring strategic partnerships.
Summary
Conduit Pharmaceuticals is a development-stage pharmaceutical company with a focus on acquiring and advancing late-stage drug candidates. Its strategy is to reduce risk by focusing on assets with existing clinical data. However, the company is reliant on successful trial outcomes and faces intense competition from larger, established players. It will need to execute flawlessly on its clinical development plans and potentially seek strategic partnerships to achieve long-term success.
Similar Companies
- NVO
- LLY
- ABBV
- JNJ
Sources and Disclaimers
Data Sources:
- Company press releases
- Company SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The analysis provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Conduit Pharmaceuticals Inc.
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2023-09-25 | CEO & Director Dr. David Joszef Tapolczay | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6 | Website https://www.conduitpharma.com |
Full time employees 6 | Website https://www.conduitpharma.com | ||
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.